Abstract 27P
Background
With the development of immune checkpoint inhibitors (ICI), microsatellite instability (MSI) has become an important biomarker. While large multigene hybrid capture next-generation sequencing (NGS) panels are highly accurate in detecting MSI, the sensitivity of small amplicon-based panels is unknown.
Methods
Next-generation sequencing (NGS) was performed on FFPE samples from patients with any stage colorectal cancer (CRC) using the Solo Atlas Pro amplicon panel covering 38 genes and 39 mononucleotide short tandem repeats for MSI analysis. 5-loci polymerase chain reaction (PCR)-based MSI analysis was used as a reference method. MSI by NGS was estimated based on the distribution of k-mers. Statistical analysis was performed using Cohen’s kappa (к), Mann Whitney and Fisher’s exact test.
Results
A total of 160 samples were analyzed using NGS and PCR. Median coverage was 2352x (range, 238-28447х), MAPD – 0.368 (range, 0.236-0.731). Based on PCR results, 42 (46.25%) samples were MSI, 118 (73.75%) – MSS. Based on NGS results, 40 (25%) samples were MSI, 120 (75%) were MSS. NGS and PCR were concordant in 98.75% (158/160) of samples (к=0.97). Sensitivity of NGS was 95.24% (95% CI, 83.84%-99.42%), specificity – 100.00% (96.92%-100.00%), accuracy – 98.75% (95.56%-99.85%). All NGS false positives cases had suboptimal FFPE quality, suggested by absence of any somatic mutations identified. MSI samples had a significantly higher amount of somatic mutations than MSS samples (median, 3 vs 1, p<0.0001). In silico mixing of the sequencing data of 11 MSI samples demonstrated that the minimal sample fraction with the detectable MSI was 0.5%; at 2.5% MSI was detectable in all samples.
Conclusions
The Atlas Pro amplicon panel demonstrates high concordance with PCR and is highly sensitive in detecting MSI in CRC samples.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation (Grant №22-75-10154).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
152P - Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping
Presenter: Khashayar Roohollahi
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - Discovery of new BRCA1/2 mutations not described in the international breast consortium
Presenter: Wala Ben Kridis
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - Alternative splicing in non-small cell lung cancer evolution
Presenter: Michelle Leung
Session: Cocktail & Poster Display session
Resources:
Abstract
155TiP - Exploring mechanisms of action and resistance to innovative therapeutic drugs: UNLOCK program
Presenter: Julieta Rodriguez
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - Therapeutic potential of B7-H3 targeting in pediatric neuroblastoma
Presenter: Caroline E Nunes-Xavier
Session: Cocktail & Poster Display session
Resources:
Abstract
158P - E-JIB-04: An epigenetic targeted therapy for ovarian cancer with MECOM amplification
Presenter: Ibha Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - The impact of kisspeptin pre-treatment towards temozolomide resistance mechanisms and associated differently expressed proteins (DEPs) in human glioblastoma cells
Presenter: Isra Sati
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - Clinical observation and immune effects of high-intensity focused ultrasound (HIFU) in the treatment of liver metastasis in colorectal cancer
Presenter: Shasha Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - Early phase cancer clinical trials: A viable treatment option for patients?
Presenter: Rhona Dawson
Session: Cocktail & Poster Display session
Resources:
Abstract
162P - Tailoring patient molecular selection for novel anti-MET therapies
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract